Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 18/20 | 0.72 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541642 | 0.90 | STING1 (0.62) | STING1CYP3A4 | |
| SCHEMBL19436550 | 0.84 | STING1 (1.00) | STING1ENPP1CYP3A4 | |
| SCHEMBL20075465 | 0.83 | STING1 (0.55) | STING1 | |
| SCHEMBL23346482 | 0.82 | STING1 (0.86) | STING1CYP3A4 | |
| SCHEMBL22541776 | 0.82 | STING1 (0.74) | STING1 | |
| SCHEMBL22541644 | 0.81 | STING1 (0.75) | STING1CYP3A4 | |
| SCHEMBL21158102 | 0.81 | STING1 (0.71) | STING1CYP3A4 | |
| SCHEMBL21158101 | 0.80 | STING1 (0.67) | STING1CYP3A4 | |
| SCHEMBL22135175 | 0.80 | STING1 (0.58) | STING1 | |
| SCHEMBL24467544 | 0.79 | STING1 (0.81) | STING1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | STING1 1/4885ENPP1 529/4885CYP3A4 521/4885 |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | STING1, CGAS, MAVS | STING1 1/4885ENPP1 529/4885CYP3A4 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.